The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Hypoxia-inducible factors: cancer progression and clinical translation
Open accessAbstract
Hypoxia-inducible factors (HIFs) are master regulators of oxygen homeostasis that match O2 supply and demand for each of the 50 trillion cells in the adult human body. Cancer cells co-opt this homeostatic system to drive cancer progression. HIFs activate the transcription of thousands of genes that mediate angiogenesis, cancer stem cell specification, cell motility, epithelial-mesenchymal transition, extracellular matrix remodeling, glucose and lipid metabolism, immune evasion, invasion, and metastasis. In this Review, the mechanisms and consequences of HIF activation in cancer cells are presented. The current status and future prospects of small-molecule HIF inhibitors for use as cancer therapeutics are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601 · cited 14×
“and fatty acids, which is mediated by HIF-dependent expression of the mitochondrial proteins BNIP3 (56) and BNIP3L (57).”
BackgroundInfluentialSelf-citationRetractedLysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedGilkes, D. M., Bajpai, S., Chaturvedi, P., Wirtz, D., & Semenza, G. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442939 · Cited by 467
Self-citationRetractedSamanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
Self-citationRetractedRETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
Self-citationRetractedRETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
Self-citationRetractedProcollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
Self-citationRetractedSamanta, D., Park, Y., Andrabi, S. A., Shelton, L. M., Gilkes, D. M., & Semenza, G. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0530 · Cited by 238
Self-citationRetractedGilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184 · cited 1×
“Clearly, the prevailing view that cells switched their metabolism because O 2 was limiting for oxidative phosphory-Figure focal adhesion formation in a HIF-dependent manner (85).”
BackgroundSelf-citationRetractedChen, Z., Zhu, Y., Dong, Y., Zhang, P., Han, X., Jin, J., & Ma, X. (2017) · Clinical Science · doi:10.1042/cs20171069 · Cited by 58
RetractedMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Self-citationEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009
Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase)
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., et al. (1996) · Science · doi:10.1126/science.273.5272.245 · Cited by 2,884
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
Self-citationPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Biomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299 · cited 1×
“In many cancers, EMT is controlled by a group of transcriptional repressors, including SNAIL, SLUG, TWIST, ZEB1, and ZEB2 (65), which downregulate the expression of E-cadherin and other epithelial cell–specific genes, and one or more of these repressors are HIF-regulated in many cancers (66–80).”
BackgroundConcepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
(1999) · PubMed · Cited by 2,204
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationAccelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Signaling from Rho to the Actin Cytoskeleton Through Protein Kinases ROCK and LIM-kinase
Maekawa, M., Ishizaki, T., Boku, S., Watanabe, N., Fujita, A., Iwamatsu, A., Obinata, T., Ohashi, K., Mizuno, K., & Narumiya, S. (1999) · Science · doi:10.1126/science.285.5429.895 · Cited by 1,636
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 1×
“HIF transcriptional activity is further modulated by factor inhibiting HIF-1 (FIH-1), which hydroxylates an asparagine residue in the transactivation domain of HIF-α subunits, thereby blocking binding of the coactivator proteins p300 and CBP (17, 18).”
BackgroundHypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520
Self-citationInhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,516
Self-citationBellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., & Mazure, N. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00166-09 · Cited by 1,501
(2000) · PubMed · Cited by 1,445
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Self-citationDirect regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345
Rankin, E. B., & Giaccia, A. J. (2016) · Science · doi:10.1126/science.aaf4405 · Cited by 1,340
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Self-citationHypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“Activation of receptor tyrosine kinases, such as the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), leads to increased mTOR activity and increased HIF-1α mRNA translation into protein in prostate (30) and breast (32) cancer, respectively.”
BackgroundSelf-citationErler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.012 · Cited by 1,231
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed · Cited by 1,230
Self-citationHIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells
Fukuda, R., Zhang, H., Kim, J.-W., Shimoda, L., Dang, C. V., & Semenza, G. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.047 · Cited by 1,225 · cited 1×
“…to maintain redox homeostasis include alternative subunits of ETC complex I (NDU-FA4L2) and complex IV (COX4I2) that serve to either decrease the flow of electrons into the ETC at complex I (58) or increase the efficiency of electron transfer out of the ETC to O 2 at complex IV (59), respectively.”
BackgroundSelf-citationTranscriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Self-citationDu, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Saini, M., Bäuerle, T., Wallwiener, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2576 · Cited by 1,047
Gao, X., Wu, G., Gu, X., Fu, L., & Mei, C. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000355743 · Cited by 1,035
Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology
Kierans, S. J., & Taylor, C. T. (2021) · The Journal of Physiology · doi:10.1113/jp280572 · Cited by 1,015
Cox, T. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 976
Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., He, X., & Semenza, G. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602883113 · Cited by 971
Self-citationRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Self-citationHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 1×
“…the large battery of HIF-regulated RNAs (>7000 identified to date), in aggregate these RNAs contribute to every critical aspect of cancer progression, including tumor vascularization, metabolic reprogramming, cell motility and invasion, and resistance to chemotherapy and radiation therapy (34–36).”
BackgroundSelf-citationZhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., & Semenza, G. L. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.001 · Cited by 885
Self-citationLoss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq
Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C. W., Ratcliffe, P. J., & Mole, D. R. (2011) · Blood · doi:10.1182/blood-2010-10-314427 · Cited by 724
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 3×
“PT2399 (belzutifan) showed efficacy against RCC and other tumors in patients with von Hippel-Lindau syndrome in a phase III trial (140) and was recently approved by the FDA for this indication (167).”
BackgroundMethodTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Chan, S. Y., Zhang, Y.-Y., Hemann, C., Mahoney, C. E., Zweier, J. L., & Loscalzo, J. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.015 · Cited by 702 · cited 1×
“HIF-1–mediated expression of the microRNA miR-210 inhibits the expression of the iron-sulfur cluster scaffold proteins ISCU1 and ISCU2, which are required for complex I assembly, thereby decreasing mitochondrial respiration (60, 61).”
BackgroundAntiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 2×
“HIF inhibitors that have shown antitumor activity in mouse tumor models include acriflavine (47), digoxin (106), echinomycin (156), the HSP90 inhibitors 17-allylaminogeldanamycin (157) and ganetespib (158), 2-methoxyestradiol (159), PX-478 (160), and YC-1 (161).”
BackgroundSelf-citationDisrupting proton dynamics and energy metabolism for cancer therapy
Parks, S. K., Chiche, J., & Pouysségur, J. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3579 · Cited by 607
(2001) · PubMed · Cited by 605
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C. M., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., & van der Wall, E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.309 · Cited by 593
Self-citationThe actin cytoskeleton in cancer cell motility
Olson, M. F., & Sahai, E. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9174-2 · Cited by 572
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling
Rey, S., & Semenza, G. L. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq045 · Cited by 540
Self-citationThe hypoxic tumor microenvironment: A driving force for breast cancer progression
Semenza, G. L. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.036 · Cited by 535 · cited 1×
“Metastasis is not listed as a separate category because it is dependent on all of the processes described below (43–45).”
BackgroundSelf-citationSox2 expression in breast tumours and activation in breast cancer stem cells
Leis, O., Eguiara, A., Lopez-Arribillaga, E., Alberdi, M. J., Hernandez-Garcia, S., Elorriaga, K., Pandiella, A., Rezola, R., & Martin, A. G. (2012) · Oncogene · doi:10.1038/onc.2011.338 · Cited by 514
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508 · cited 1×
“HIF inhibitors that have shown antitumor activity in mouse tumor models include acriflavine (47), digoxin (106), echinomycin (156), the HSP90 inhibitors 17-allylaminogeldanamycin (157) and ganetespib (158), 2-methoxyestradiol (159), PX-478 (160), and YC-1 (161).”
BackgroundHIF Induces Human Embryonic Stem Cell Markers in Cancer Cells
Mathieu, J., Zhang, Z., Zhou, W., Wang, A. J., Heddleston, J. M., Pinna, C. M. A., Hubaud, A., Stadler, B., Choi, M., Bar, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3320 · Cited by 508
The Effect of Oxygen on Biochemical Networks and the Evolution of Complex Life
Raymond, J., & Segrè, D. (2006) · Science · doi:10.1126/science.1118439 · Cited by 502
Liu, Y. V., Baek, J. H., Zhang, H., Diez, R., Cole, R. N., & Semenza, G. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.001 · Cited by 478
Self-citationYC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Yeo, E.-J., Chun, Y.-S., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.516 · Cited by 476
Yu, F., Li, J., Chen, H., Fu, J., Ray, S., Huang, S., Zheng, H., & Ai, W. (2011) · Oncogene · doi:10.1038/onc.2010.591 · Cited by 473
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
Wong, C. C.-L., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., Fraley, S. I., Wong, C.-M., Khoo, U.-S., Ng, I. O.-L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113483108 · Cited by 437 · cited 3×
“In an orthotopic mouse model, cross-linked collagen and CD45 + CD11b + cells were detected in the lungs on days 7 and 14 after breast cancer cell implantation in the mammary fat pad, whereas cancer cells were not detected in the lungs until day 21 (103).”
BackgroundZhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420 · cited 1×
“In breast cancer patients, circulating tumor cells in peripheral blood with metastasis-initiating capability when injected into mice were found to express CD44, CD47, and MET (136), which are all encoded by HIF target genes (137–139).”
BackgroundSelf-citationKrishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., & Semenza, G. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3719 · Cited by 415
Self-citationJayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399 · cited 1×
“However, it appears that the net effect of hypoxia in most tumors is immunosuppression, and administration of supplemental O2 (151) or a drug that is selectively toxic to hypoxic cells (152) is sufficient to increase the number of intratumoral T cells and the response to immunotherapy.”
BackgroundKrieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396 · cited 1×
“In these VHL-null tumors, cancer cells are strongly positive for HIF-1α and/or HIF-2α by immunohistochemistry (27, 28).”
BackgroundCourtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Favaro, E., Bensaad, K., Chong, M. G., Tennant, D. A., Ferguson, D. J. P., Snell, C., Steers, G., Turley, H., Li, J.-L., Günther, U. L., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.017 · Cited by 386
HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V., & Caro, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110978200 · Cited by 370
Tello, D., Balsa, E., Acosta-Iborra, B., Fuertes-Yebra, E., Elorza, A., Ordóñez, Á., Corral-Escariz, M., Soro, I., López-Bernardo, E., Perales-Clemente, E., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.008 · Cited by 368
Structural integration in hypoxia-inducible factors
Wu, D., Potluri, N., Lu, J., Kim, Y., & Rastinejad, F. (2015) · Nature · doi:10.1038/nature14883 · Cited by 346
Sun, R. C., & Denko, N. C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.022 · Cited by 344 · cited 1×
“HIF-1 can also block the production of reducing equivalents in the TCA cycle by increased expression of SIAH2, which ubiquitinates the TCA cycle enzyme α-ketoglutarate dehydrogenase, targeting it for degradation (62).”
BackgroundA Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J.-L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010345 · Cited by 324 · cited 1×
“HIF-1–mediated expression of the microRNA miR-210 inhibits the expression of the iron-sulfur cluster scaffold proteins ISCU1 and ISCU2, which are required for complex I assembly, thereby decreasing mitochondrial respiration (60, 61).”
BackgroundHypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Bao, M. H.-R., & Wong, C. C.-L. (2021) · Cells · doi:10.3390/cells10071715 · Cited by 316 · cited 1×
“…the large battery of HIF-regulated RNAs (>7000 identified to date), in aggregate these RNAs contribute to every critical aspect of cancer progression, including tumor vascularization, metabolic reprogramming, cell motility and invasion, and resistance to chemotherapy and radiation therapy (34–36).”
BackgroundChoueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305 · cited 2×
“Both compounds showed safety and activity against advanced RCC in phase I trials (165, 166).”
BackgroundSamanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302 · cited 3×
“In recent studies using mouse models of breast cancer described above (153) and hepatocellular carcinoma described below, we have found that the net effect of pharmacologic inhibition of HIFs is to significantly increase antitumor immunity.”
BackgroundInfluentialSelf-citationJoseph, J. V., Conroy, S., Pavlov, K., Sontakke, P., Tomar, T., Eggens-Meijer, E., Balasubramaniyan, V., Wagemakers, M., den Dunnen, W. F. A., & Kruyt, F. A. E. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.010 · Cited by 302
Bosch-Marce, M., Okuyama, H., Wesley, J. B., Sarkar, K., Kimura, H., Liu, Y. V., Zhang, H., Strazza, M., Rey, S., Savino, L., et al. (2007) · Circulation Research · doi:10.1161/circresaha.107.153346 · Cited by 297
Self-citationPharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
Self-citationBraun, R. D., Lanzen, J. L., Snyder, S. A., & Dewhirst, M. W. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.6.h2533 · Cited by 285 · cited 1×
“6 mmHg, which corresponds to approximately 1% O2 (2).”
BackgroundHIF-1 mediates the Warburg effect in clear cell renal carcinoma
Semenza, G. L. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9081-2 · Cited by 281
Self-citationWelsh, S. J., Williams, R. R., Kirkpatrick, L., Paine-Murrieta, G. D., & Powis, G. (2004) · PubMed · Cited by 280
Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 269
Self-citationZhang, W., Shi, X., Peng, Y., Wu, M., Zhang, P., Xie, R., Wu, Y., Yan, Q., Liu, S., & Wang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129603 · Cited by 261
Zhang, C., Zhi, W. I., Lu, H., Samanta, D., Chen, I., Gabrielson, E., & Semenza, G. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11743 · Cited by 259
Self-citationRevisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256 · cited 3×
“A recent review summarized the experimental data supporting the concept that HIF-1 and HIF-2 play complementary roles in many cancers and that targeting both HIF-1 and HIF-2 for inhibition will provide greater therapeutic benefit than targeting either one of them alone (39).”
BackgroundResultThe Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia
Schietke, R., Warnecke, C., Wacker, I., Schödel, J., Mole, D. R., Campean, V., Amann, K., Goppelt-Struebe, M., Behrens, J., Eckardt, K.-U., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042424 · Cited by 253
Mimura, I., Nangaku, M., Kanki, Y., Tsutsumi, S., Inoue, T., Kohro, T., Yamamoto, S., Fujita, T., Shimamura, T., Suehiro, J.-I., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06643-11 · Cited by 251
Telomeres and telomerase in normal and cancer stem cells
Shay, J. W., & Wright, W. E. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.026 · Cited by 251
Kong, T., Eltzschig, H. K., Karhausen, J., Colgan, S. P., & Shelley, C. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401339101 · Cited by 242
Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.233.3.3 · Cited by 240
Wong, C. C.-L., Zhang, H., Gilkes, D. M., Chen, J., Wei, H., Chaturvedi, P., Hubbi, M. E., & Semenza, G. L. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0855-y · Cited by 225
Self-citationSchito, L., Rey, S., Tafani, M., Zhang, H., Wong, C. C.-L., Russo, A., Russo, M. A., & Semenza, G. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214019109 · Cited by 224
Self-citationOctamer 4 Small Interfering RNA Results in Cancer Stem Cell–Like Cell Apoptosis
Hu, T., Liu, S., Breiter, D. R., Wang, F., Tang, Y., & Sun, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6642 · Cited by 217
Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaib, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 212
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Self-citationBrooks, D. L. P., Schwab, L. P., Krutilina, R., Parke, D. N., Sethuraman, A., Hoogewijs, D., Schörg, A., Gotwald, L., Fan, M., Wenger, R. H., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0510-x · Cited by 190
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W.-H., & Wong, C. C.-L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 183
Camps, C., Saini, H. K., Mole, D. R., Choudhry, H., Reczko, M., Guerra‐Assunção, J. A., Tian, Y., Buffa, F. M., Harris, A. L., Hatzigeorgiou, A. G., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-28 · Cited by 182
Hypoxic Induction of Prolyl 4-Hydroxylase α(I) in Cultured Cells
Takahashi, Y., Takahashi, S., Shiga, Y., Yoshimi, T., & Miura, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.19.14139 · Cited by 174
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 169
Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment
Lu, H., Chen, I., Shimoda, L. A., Park, Y., Zhang, C., Tran, L., Zhang, H., & Semenza, G. L. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.001 · Cited by 168
Self-citationLiikanen, I., Lauhan, C. R., Quon, S., Omilusik, K. D., Phan, A. T., Bartrolí, L. B., Ferry, A., Goulding, J., Chen, J., Scott-Browne, J. P., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143729 · Cited by 167
Oxygen tension regulates the expression of a group of procollagen hydroxylases
Hofbauer, K., Gess, B., Lohaus, C., Meyer, H. E., Katschinski, D., & Kurtz, A. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03846.x · Cited by 162
Gale, D. P., Harten, S. K., Reid, C. D. L., Tuddenham, E. G. D., & Maxwell, P. H. (2008) · Blood · doi:10.1182/blood-2008-04-153718 · Cited by 157
The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α
Gort, E. H., van Haaften, G. W., Verlaan-Klink, I., Groot, A. J., Plasterk, R. H. A., Shvarts, A., Suijkerbuijk, K. P. M., van Laar, T., van der Wall, E., Raman, V., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210795 · Cited by 157
HIF1α Represses Cell Stress Pathways to Allow Proliferation of Hypoxic Fetal Cardiomyocytes
Guimarães‐Camboa, N., Stowe, J. C., Aneas, I., Sakabe, N. J., Cattaneo, P., Henderson, L. M., Kilberg, M. S., Johnson, R. S., Chen, J., McCulloch, A. D., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.04.021 · Cited by 154
Hypoxia-inducible Factor Regulates αvβ3 Integrin Cell Surface Expression
Dahl, K. D. C., Robertson, S. E., Weaver, V. M., & Simon, M. C. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1082 · Cited by 150
The Genomics and Genetics of Oxygen Homeostasis
Semenza, G. L. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111119-073356 · Cited by 148
Self-citationHypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
Krishnamachary, B., Penet, M., Nimmagadda, S., Mironchik, Y., Raman, V., Solaiyappan, M., Semenza, G. L., Pomper, M. G., & Bhujwalla, Z. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044078 · Cited by 145
Self-citationChemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness
Lu, H., Xie, Y., Tran, T. M. L., Lan, J., Yang, Y., Murugan, N. L., Wang, R., Wang, Y. J., & Semenza, G. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138577 · Cited by 144
Self-citationJu, J. A., Godet, I., Ye, I. C., Byun, J., Jayatilaka, H., Lee, S. J., Xiang, L., Samanta, D., Lee, M., Wu, P.-H., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0338 · Cited by 143
Self-citationEmerging role of nanog in tumorigenesis and cancer stem cells
Santaliz-Ruiz, L. E. I., Xie, X., Old, M. O., Teknos, T. N., & Pan, Q. (2013) · International Journal of Cancer · doi:10.1002/ijc.28690 · Cited by 142
Lan, J., Lu, H., Samanta, D., Salman, S., Lü, Y., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809695115 · Cited by 137
Self-citationMaintenance of redox homeostasis by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2017) · Redox Biology · doi:10.1016/j.redox.2017.05.022 · Cited by 127 · cited 1×
“HIF-1 plays a critical role as master regulator of the balance between oxidative and glycolytic metabolism (50).”
BackgroundSelf-citationRole of hypoxia inducible factor-1 in cancer stem cells (Review)
Zhang, Q., Han, Z., Zhu, Y., Chen, J., & Li, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11655 · Cited by 123
Xiang, L., Gilkes, D. M., Hu, H., Takano, N., Luo, W., Lu, H., Bullen, J. W., Samanta, D., Liang, H., & Semenza, G. L. (2014) · Oncotarget · doi:10.18632/oncotarget.2997 · Cited by 119
Self-citationMouse Snail Is a Target Gene for HIF
Luo, D., Wang, J., Li, J., & Post, M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0214 · Cited by 116
Xiang, L., Gilkes, D. M., Chaturvedi, P., Luo, W., Hu, H., Takano, N., Liang, H., & Semenza, G. L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1102-5 · Cited by 114 · cited 1×
“HIF inhibitors that have shown antitumor activity in mouse tumor models include acriflavine (47), digoxin (106), echinomycin (156), the HSP90 inhibitors 17-allylaminogeldanamycin (157) and ganetespib (158), 2-methoxyestradiol (159), PX-478 (160), and YC-1 (161).”
BackgroundSelf-citationSalman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111 · cited 5×
“In immunocompetent mice bearing Hepa1-6 mouse HCC tumors, combined treatment with 32-134D and anti–PD-1 antibody resulted in tumor eradication in 67% of the mice compared with 25% of the mice treated with anti–PD-1 alone (177).”
BackgroundInfluentialSelf-citationThe TIP60 Complex Is a Conserved Coactivator of HIF1A
Perez-Perri, J. I., Dengler, V. L., Audetat, K. A., Pandey, A., Bonner, E. A., Urh, M., Méndez, J., Daniels, D. L., Wappner, P., Galbraith, M. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.082 · Cited by 107
Chen, S., Chen, J.-Z., Zhang, J., Chen, H., Yan, M.-L., Huang, L., Tian, Y., Chen, Y., & Wang, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.027 · Cited by 106
Ottensmeier, C. H. H., Perry, K. L., Harden, E. L., Stasakova, J., Jenei, V., Fleming, J. C., Wood, O., Woo, J., Woelk, C. H., Thomas, G. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3121 · Cited by 103
Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis
Wang, R., Godet, I., Yang, Y., Salman, S., Lu, H., Lyu, Y., Zuo, Q., Wang, Y., Zhu, Y., Chen, C. O., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020490118 · Cited by 103
Self-citationWang, Y., Lyu, Y., Tu, K., Xu, Q., Yang, Y., Salman, S., Le, N., Lu, H., Chen, C. O., Zhu, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3771 · Cited by 103
Self-citationLu, H., Tran, T. M. L., Park, Y., Chen, I., Lan, J., Xie, Y., & Semenza, G. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0270 · Cited by 101
Self-citationHypoxia Pathway Proteins are Master Regulators of Erythropoiesis
Watts, D., Gaete, D., Rodriguez, D., Hoogewijs, D., Rauner, M., Sormendi, S., & Wielockx, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218131 · Cited by 101
Liu, X., Xie, P., Hao, N., Zhang, M., Liu, Y., Liu, P., Semenza, G. L., He, J., & Zhang, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109144118 · Cited by 101
Self-citationHypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 97
Yang, S.-W., Zhang, Z., Hao, Y., Zhao, Y., Qian, F., Shi, Y., Li, P., Liu, C.-Y., & Yu, P.-W. (2017) · Oncotarget · doi:10.18632/oncotarget.14484 · Cited by 89
Cheng, J., Klausen, C., & Leung, P. C. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.029 · Cited by 84
Chang, J., & Erler, J. T. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_3 · Cited by 83
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
Depner, C., Buttel, H. Z., Böğürcü, N., Cuesta, Á. M., Aburto, M. R., Seidel, S., Finkelmeier, F., Foss, F., Hofmann, J., Kaulich, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms12329 · Cited by 81
Vaupel, P. W., Flood, A. B., & Swartz, H. M. (2021) · Applied Magnetic Resonance · doi:10.1007/s00723-021-01383-6 · Cited by 79
Gao, H., Teng, C.-Y., Huang, W., Peng, J.-J., & Wang, C.-B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160921643 · Cited by 76
Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Hatfield, S. M., & Sitkovsky, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137554 · Cited by 73
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71 · cited 2×
“Finally, it should be emphasized that hypoxia-induced breast CSC specification is mediated by HIF-1 α only (38, 122), such that selective inhibition of HIF-2 α (140), by inhibiting angiogenesis and increasing intratumoral hypoxia, might result in a counter-therapeutic increase in CSCs. Cancer stem…”
BackgroundSelf-citationIntratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Self-citationAndrysik, Z., Bender, H., Galbraith, M. D., & Espinosa, J. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21687-2 · Cited by 63
Hypoxia pathway proteins and their impact on the blood vasculature
Rodriguez, D., Watts, D., Gaete, D., Sormendi, S., & Wielockx, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179191 · Cited by 62
Loftus, S. K., Baxter, L. L., Cronin, J. C., Fufa, T., Program, N. C. S., & Pavan, W. J. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12579 · Cited by 59
The regulation of transcriptional repression in hypoxia
Cavadas, M. A. S., Cheong, A., & Taylor, C. T. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.024 · Cited by 59
Lu, H., Lyu, Y., Tran, T. M. L., Lan, J., Xie, Y., Yang, Y., Murugan, N. L., Wang, Y. J., & Semenza, G. L. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109757 · Cited by 58
Self-citationBIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Self-citationWierenga, A. T. J., Cunningham, A., Erdem, A., Vilaplana‐Lopera, N., Brouwers-Vos, A. Z., Pruis, M. G. M., Mulder, A. B., Günther, U. L., Martens, J. H. A., Vellenga, E., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0206-y · Cited by 48
Cao, S., Yang, S., Wu, C., Wang, Y., Jiang, J., & Lu, Z. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.04.004 · Cited by 45
Couvé, S., Ladroue, C., Laine, É., Mahtouk, K., Guégan, J., Gad, S., Jeune, H. L., Gentil, M. L., Nuel, G., Kim, W. Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1161 · Cited by 45
Breakthrough science: hypoxia-inducible factors, oxygen sensing, and disorders of hematopoiesis
Semenza, G. L. (2021) · Blood · doi:10.1182/blood.2021011043 · Cited by 42
Self-citationLiu, K.-H., Tsai, Y.-T., Chin, S., LEE, W.-R., Chen, Y., & Shen, S. (2018) · Anticancer Research · doi:10.21873/anticanres.12986 · Cited by 41
Gordeuk, V. R., Miasnikova, G., Sergueeva, A., Lorenzo, F., Zhang, X., Song, J., Stockton, D. W., & Prchal, J. T. (2019) · Haematologica · doi:10.3324/haematol.2019.216267 · Cited by 41
Liu, Y., Liu, Y., Yan, X., Xu, Y., Luo, F., Ye, J., Yan, H., Yang, X., Huang, X., Zhang, J., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2056-0 · Cited by 37
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Lai, E., Astara, G., Ziranu, P., Pretta, A., Migliari, M., Dubois, M., Donisi, C., Mariani, S., Liscia, N., Impera, V., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103167 · Cited by 35
Xu, R., Zhang, Y., Li, A., Ma, Y., Cai, W., Li, S., Xie, Y., Zhou, S., Cao, W., & Tang, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12147 · Cited by 34
Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing
Zhang, X., Zhang, W., Ma, S., Miasniakova, G., Sergueeva, A., Ammosova, T., Xu, M., Nekhai, S. A., Nourai, M., Wade, M. S., et al. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.07.016 · Cited by 28
Hoefflin, R., Harlander, S., Abhari, B. A., Peighambari, A., Adlesic, M., Seidel, P., Zodel, K., Haug, S., Göçmen, B., Li, Y., et al. (2021) · Cancers · doi:10.3390/cancers13194801 · Cited by 16
Neddylation blockade induces HIF-1α driven cancer cell migration via upregulation of ZEB1
Park, J. B., Seo, J., Park, J., & Chun, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-75286-0 · Cited by 12
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
Bae, T., Hallis, S. P., & Kwak, M.-K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01180-8 · Cited by 354
The role of lipid metabolic reprogramming in tumor microenvironment
Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023) · Theranostics · doi:10.7150/thno.82920 · Cited by 270
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
Metadata
- Authors
- Wicks, E. E., & Semenza, G. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-06-01
- Volume
- 132
- Issue
- 11
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4282015487
- Cited by
- 580
- References
- 179
- FWCI
- 39.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.